Anti-PHF-tau antibodies and their uses
Anti-PHF-tau antibodies and methods of making and using them are disclosed.
1. An isolated antibody that binds PHF-tau comprising an antigen-binding site of a heavy chain variable region (VH) of SEQ ID NO:35 or 37, and an antigen-binding site of a light chain variable region (VL) of SEQ ID NO:36 or 38.
2. An isolated antibody that binds PHF-tau, wherein the antigen-binding site of the VH comprises heavy chain complementarity determining regions (CDRs) 1 (HCDR1), 2 (HCDR2) and 3 (HCDR3) of SEQ ID NOs:7, 8 and 9 or SEQ ID NOs:13, 14 and 15, respectively, and the antigen-binding site of the VL comprises light chain CDRs 1 (LCDR1), 2 (LCDR2) and 3 (LCDR3) of SEQ ID NOs:10, 11 and 12 or SEQ ID NOs: 16, 17 and 18, respectively.
3. The isolated antibody of claim 1 that binds PHF-tau comprising an antigen-binding site of a VH of SEQ ID NO:35 and an antigen-binding site of a VL of SEQ ID NO:36.
4. The isolated antibody of claim 2 , wherein the antigen-binding site of the VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:7, 8 and 9, respectively, and the antigen-binding site of the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:10, 11 and 12, respectively.
5. The isolated antibody of claim 1 that binds PHF-tau comprising an antigen-binding site of a VH of SEQ ID NO:37 and an antigen-binding site of a VL of SEQ ID NO: 38.
6. The isolated antibody of claim 2 , wherein the antigen-binding site of the VH comprises HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:13, 14 and 15, respectively, and the antigen-binding site of the VL comprises LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:16, 17 and 18, respectively.
7. The isolated antibody of any one of claims 1 - 6 , wherein the antibody is humanized.
8. An isolated polynucleotide encoding an antibody VH comprising HCDR1, HCDR2 and HCDR3 of SEQ ID NOs:7, 8 and 9, respectively, or SEQ ID NOs:13, 14 and 15, respectively.
9. An isolated polynucleotide encoding an antibody VL comprising LCDR1, LCDR2 and LCDR3 of SEQ ID NOs:10, 11 and 12, respectively, or SEQ ID NOs:16, 17 and 18, respectively.
10. A vector comprising a polynucleotide of claim 8 or 9 .
11. A host cell comprising the vector of claim 10 .